Suppression of 8-oxo-2'-deoxyguanosine formation and carcinogenesis induced by N-nitrosobis (2-oxopropyl)amine in hamsters by esculetin and esculin.
Effects of esculetin (6,7-dihydroxycoumarin) and its glycoside, esculin, on 8-oxo-2'-deoxyguanosine (8-oxodG) formation and carcinogenesis induced by a chemical carcinogen, N-nitrosobis(2-oxopropyl)amine (BOP), were examined in the pancreas of female Syrian golden hamsters. Animals were administered esculetin by gastric intubation into the stomach 30 min before BOP administration or ingestion of a diet containing esculin for 7 days before BOP administration, and killed 1 or 4h after BOP treatment, and the contents of thiobarbituric acid-reacting substrates (TBARS) and 8-oxodG in the pancreas were determined. Both compounds suppressed significantly the BOP-induced increases in 8-oxodG and TBARS contents in hamster pancreas. We further investigated the effect of esculin on pancreatic carcinogenesis by the rapid production model induced by augmentation pressure with a choline-deficient diet, ethionine, methionine and BOP. Esculin was given ad libitum as a 0.05% aqueous solution in either the initiation or promotion phases. The incidence of invasive tumors in animals given esculin during the initiation phase was significantly smaller than in the control group, while esculin given during the promotion phase showed no apparent effects. These results suggest that the intake of esculin has an inhibitory effect on BOP-induced oxidative DNA damage and carcinogenesis in hamster pancreas.
Kaneko
Takao
T
Redox Regulation Research Group, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakaecho, Itabashi-ku, Tokyo 173-0015, Japan. kaneko@tmig.or.jp
Tahara
Shoichi
S
Takabayashi
Fumiyo
F
Harada
Noboru
N
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000821:Animal Feed; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002273:Carcinogens / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D002467:Cell Nucleus / Q000187:drug effects / Q000378:metabolism; D002794:Choline / Q000494:pharmacology; D006224:Cricetinae; D004247:DNA / Q000378:metabolism; D003849:Deoxyguanosine / Q000031:analogs & derivatives* / Q000378:metabolism*; D004929:Esculin / Q000494:pharmacology*; D005001:Ethionine / Q000494:pharmacology; D005260:Female; D008715:Methionine / Q000494:pharmacology; D009602:Nitrosamines / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D009929:Organ Size / Q000187:drug effects; D010084:Oxidation-Reduction / Q000187:drug effects; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014468:Umbelliferones / Q000494:pharmacology*
D002273:Carcinogens; D009602:Nitrosamines; D017392:Thiobarbituric Acid Reactive Substances; D014468:Umbelliferones; D004929:Esculin; C013622:nitrosobis(2-oxopropyl)amine; D000080242:8-Hydroxy-2'-Deoxyguanosine; D004247:DNA; D008715:Methionine; D003849:Deoxyguanosine; D002794:Choline; C007628:esculetin; D005001:Ethionine